Premium
Prescribing in borderline personality disorder – the clinical guidelines
Author(s) -
Yadav Devender
Publication year - 2020
Publication title -
progress in neurology and psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.19
H-Index - 12
eISSN - 1931-227X
pISSN - 1367-7543
DOI - 10.1002/pnp.667
Subject(s) - borderline personality disorder , polypharmacy , authorization , psychiatry , medical prescription , food and drug administration , medicine , drug , placebo , clinical psychology , alternative medicine , intensive care medicine , pharmacology , computer security , pathology , computer science
Drug prescription and polypharmacy are commonly seen in the management of borderline personality disorder (BPD) in clinical practice, and the ‘placebo effect of medications’ in BPD patients is significant. However, it is to be noted that ‘no drug’ has a UK market authorisation or Food & Drug Administration approval in the USA for BPD. Here Dr Yadav reviews the guidelines.